The aim of COSMIC Mutation Actionability in Precision Oncology product (Actionability) is to indicate the availability of drugs that target mutations in cancer and track the progress of clinical studies towards making new drugs available. Drugs that target somatic mutations are represented at all stages of drug development, through safety and clinical phases to market and repurposing, with additional case studies.

The principal units of actionability are mutation, disease, and drug. Capturing relations between these units allows identification of existing and upcoming drugs that target particular genetic variants in specific cancer types.

To find out more about the Actionability product, please click here.